

AMENDMENTS TO THE SPECIFICATION:

Please insert the following paragraph before the Introduction on page 1:

CROSS REFERENCE TO RELATED APPLICATION

The present application claims priority to U.S. Patent Application No. 09/370,337, filed August 6, 1999, now U.S Patent No. 6,645,465 B2, entitled ANNEXIN PROTEINS AND AUTOANTIBODIES AS SERUM MARKERS FOR CANCER.

Please replace paragraph [0018] with the following:

Figures 4A-D. IgG subtype immunoreactivity against lung cancer patient sera. Western blots of a two-dimensional gel separation of A549 lysates with serum from lung cancer patients. Membranes were subsequently hybridized with horseradish peroxidase-conjugated mouse anti-human IgG1(A), IgG2(B), IgG3(C) or IgG4(D) antibody.

Please replace paragraph [0019] with the following:

Figures 5A-D. Specificity of A1 and A2 IgG antibodies to lung cancer patient sera. Membranes containing A549 lysates were hybridized with sera from patients with melanoma, breast cancer, liver cancer or esophageal cancer. None of the sera exhibited IgG based immunoreactivity against A2. A1 proteins were observed with sera from patients with esophageal cancer (5/8) (A), breast cancer (1/11) (B), but were absent with sera from patients with melanoma, (0/7) (C) and liver cancer (0/11) (D).

Please replace paragraph [0020] with the following:

Figures 6A and B. Anti-Annexin I (A), and anti-Annexin II (B) antibodies are immunoreactive against proteins in the A1 and A2 spots respectively.